SINGAPORE (Reuters) – According to a study published in The Lancet Medical Journal by researchers in Singapore this week, a new version of the COVID-19 coronavirus has been found to cause myelor infections.
The study showed that COVID-19 patients infected with a new version of SARS-CoV-2 had better clinical outcomes, with lower ratios developing lower blood oxygen or requiring intensive care.
The study also showed the variant, which has a large deletion in one part of the genome, elicited a more robust immune response.
The study involved researchers from various Singaporean institutions, including the National Center for Infectious Diseases (NCID), Duke-NUS Medical School and the Science, Technology and Research Agency.
Gavin Smith at Duke-NUS stated, “These studies show that genetic changes (mutations) seen in SARS-COV-2 have affected the severity of the disease in patients.”
The scientists said the findings had implications for vaccine development and treatment for COVID-19.
The variant, which presumably came from Wuhan, China, was found in a group of infections from January to March 2020. In Singapore, the virus was included in several groups from person to person.
An expert told Reuters this week that mutations in the virus could be “a good thing”. According to Paul Tambah at the National University Hospital in Singapore, viruses are less viral to infect more people, because they infect more people, but not to kill them, because they depend on the host for food and shelter. Huh.
Reporting by Aradhana Aravindan in Singapore; Editing by Mark Potter